GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JW Life Science Corp (XKRX:234080) » Definitions » Debt-to-Revenue

JW Life Science (XKRX:234080) Debt-to-Revenue : 0.22 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is JW Life Science Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

JW Life Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩47,462 Mil. JW Life Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩172 Mil. JW Life Science's annualized Revenue for the quarter that ended in Mar. 2024 was ₩221,337 Mil. JW Life Science's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.22.


JW Life Science Debt-to-Revenue Historical Data

The historical data trend for JW Life Science's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW Life Science Debt-to-Revenue Chart

JW Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.26 0.20 0.27 0.36 0.22

JW Life Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.26 0.26 0.22 0.22

Competitive Comparison of JW Life Science's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, JW Life Science's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW Life Science's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JW Life Science's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where JW Life Science's Debt-to-Revenue falls into.



JW Life Science Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

JW Life Science's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(46098.144 + 214.681) / 206860.372
=0.22

JW Life Science's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(47461.761 + 172.361) / 221336.944
=0.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


JW Life Science Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of JW Life Science's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


JW Life Science (XKRX:234080) Business Description

Traded in Other Exchanges
N/A
Address
28, Hanjin 1-gil, Songak-eup, Dangjin-si, Chungcheongnam-do, Seoul, KOR, 343-823
JW Life Science Corp develops and produces infusion solutions. Its products contents amino acids, lipids, proteins, vitamins, and minerals to patients.

JW Life Science (XKRX:234080) Headlines

No Headlines